Cargando…

Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking

Cancer is one of the most common diseases afflicting people globally. New therapeutic approaches are needed due to the complexity of cancer as a disease. Many current treatments are very toxic and have modest efficacy at best. Increased understanding of tumor biology and immunology has allowed the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Conniot, João, Silva, Joana M., Fernandes, Joana G., Silva, Liana C., Gaspar, Rogério, Brocchini, Steve, Florindo, Helena F., Barata, Teresa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244808/
https://www.ncbi.nlm.nih.gov/pubmed/25505783
http://dx.doi.org/10.3389/fchem.2014.00105
_version_ 1782346282178707456
author Conniot, João
Silva, Joana M.
Fernandes, Joana G.
Silva, Liana C.
Gaspar, Rogério
Brocchini, Steve
Florindo, Helena F.
Barata, Teresa S.
author_facet Conniot, João
Silva, Joana M.
Fernandes, Joana G.
Silva, Liana C.
Gaspar, Rogério
Brocchini, Steve
Florindo, Helena F.
Barata, Teresa S.
author_sort Conniot, João
collection PubMed
description Cancer is one of the most common diseases afflicting people globally. New therapeutic approaches are needed due to the complexity of cancer as a disease. Many current treatments are very toxic and have modest efficacy at best. Increased understanding of tumor biology and immunology has allowed the development of specific immunotherapies with minimal toxicity. It is important to highlight the performance of monoclonal antibodies, immune adjuvants, vaccines and cell-based treatments. Although these approaches have shown varying degrees of clinical efficacy, they illustrate the potential to develop new strategies. Targeted immunotherapy is being explored to overcome the heterogeneity of malignant cells and the immune suppression induced by both the tumor and its microenvironment. Nanodelivery strategies seek to minimize systemic exposure to target therapy to malignant tissue and cells. Intracellular penetration has been examined through the use of functionalized particulates. These nano-particulate associated medicines are being developed for use in imaging, diagnostics and cancer targeting. Although nano-particulates are inherently complex medicines, the ability to confer, at least in principle, different types of functionality allows for the plausible consideration these nanodelivery strategies can be exploited for use as combination medicines. The development of targeted nanodelivery systems in which therapeutic and imaging agents are merged into a single platform is an attractive strategy. Currently, several nanoplatform-based formulations, such as polymeric nanoparticles, micelles, liposomes and dendrimers are in preclinical and clinical stages of development. Herein, nanodelivery strategies presently investigated for cancer immunotherapy, cancer targeting mechanisms and nanocarrier functionalization methods will be described. We also intend to discuss the emerging nano-based approaches suitable to be used as imaging techniques and as cancer treatment options.
format Online
Article
Text
id pubmed-4244808
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42448082014-12-10 Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking Conniot, João Silva, Joana M. Fernandes, Joana G. Silva, Liana C. Gaspar, Rogério Brocchini, Steve Florindo, Helena F. Barata, Teresa S. Front Chem Chemistry Cancer is one of the most common diseases afflicting people globally. New therapeutic approaches are needed due to the complexity of cancer as a disease. Many current treatments are very toxic and have modest efficacy at best. Increased understanding of tumor biology and immunology has allowed the development of specific immunotherapies with minimal toxicity. It is important to highlight the performance of monoclonal antibodies, immune adjuvants, vaccines and cell-based treatments. Although these approaches have shown varying degrees of clinical efficacy, they illustrate the potential to develop new strategies. Targeted immunotherapy is being explored to overcome the heterogeneity of malignant cells and the immune suppression induced by both the tumor and its microenvironment. Nanodelivery strategies seek to minimize systemic exposure to target therapy to malignant tissue and cells. Intracellular penetration has been examined through the use of functionalized particulates. These nano-particulate associated medicines are being developed for use in imaging, diagnostics and cancer targeting. Although nano-particulates are inherently complex medicines, the ability to confer, at least in principle, different types of functionality allows for the plausible consideration these nanodelivery strategies can be exploited for use as combination medicines. The development of targeted nanodelivery systems in which therapeutic and imaging agents are merged into a single platform is an attractive strategy. Currently, several nanoplatform-based formulations, such as polymeric nanoparticles, micelles, liposomes and dendrimers are in preclinical and clinical stages of development. Herein, nanodelivery strategies presently investigated for cancer immunotherapy, cancer targeting mechanisms and nanocarrier functionalization methods will be described. We also intend to discuss the emerging nano-based approaches suitable to be used as imaging techniques and as cancer treatment options. Frontiers Media S.A. 2014-11-26 /pmc/articles/PMC4244808/ /pubmed/25505783 http://dx.doi.org/10.3389/fchem.2014.00105 Text en Copyright © 2014 Conniot, Silva, Fernandes, Silva, Gaspar, Brocchini, Florindo and Barata. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Conniot, João
Silva, Joana M.
Fernandes, Joana G.
Silva, Liana C.
Gaspar, Rogério
Brocchini, Steve
Florindo, Helena F.
Barata, Teresa S.
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title_full Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title_fullStr Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title_full_unstemmed Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title_short Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
title_sort cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244808/
https://www.ncbi.nlm.nih.gov/pubmed/25505783
http://dx.doi.org/10.3389/fchem.2014.00105
work_keys_str_mv AT conniotjoao cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT silvajoanam cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT fernandesjoanag cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT silvalianac cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT gasparrogerio cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT brocchinisteve cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT florindohelenaf cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking
AT baratateresas cancerimmunotherapynanodeliveryapproachesforimmunecelltargetingandtracking